Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

T. Tsushima, M. Noda, Y. Nasu, H. Ohmori, A. Yamamoto, H. Takigawa, S. Kagawa, Y. Matsumura, T. Matsumoto, I. Ogawa, A. Kawano, M. Nishi, S. Akazawa, S. Nakamura, K. Y. Akiyama, K. Tatara, Y. Sumiyoshi, Y. Aga, T. Yokota

    Research output: Contribution to journalArticlepeer-review

    Abstract

    A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

    Original languageEnglish
    Pages (from-to)986-991
    Number of pages6
    JournalNishinihon Journal of Urology
    Volume56
    Issue number9
    Publication statusPublished - 1994

    Keywords

    • 5-fluorouracil
    • interferon-α
    • mitomycin C
    • renal cell carcinoma

    ASJC Scopus subject areas

    • Urology

    Fingerprint

    Dive into the research topics of 'Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

    Cite this